Lorbrena and Zepatier

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Lorlatinib may significantly reduce the blood levels of grazoprevir, which may make the medication less effective in treating hepatitis C. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme. In 10 study subjects, administration of elbasvir (50 mg once daily) with the moderate CYP450 3A4 inducer efavirenz (600 mg once daily) decreased elbasvir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) by 45%, 54% and 59%, respectively, compared to administration of elbasvir alone. Likewise, when grazoprevir 200 mg once daily and efavirenz 600 mg once daily were given together to 12 study subjects, grazoprevir Cmax, AUC and Cmin decreased by 87%, 83% and 69%, respectively.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with moderate CYP450 3A4 inducers should generally be avoided.

Lorbrena

Generic Name: lorlatinib

Brand name: Lorbrena

Synonyms: n.a.

What is Lorbrena?

Zepatier

Generic Name: elbasvir / grazoprevir

Brand name: Zepatier

Synonyms: n.a.

What is Zepatier?